Serum levels of inflammatory markers and HbA1c in patients with type 2 diabetes and apical periodontitis: Preliminary findings

Abstract

This pilot study assessed the glycaemic control and the serum levels of inflammatory mediators in type 2 diabetes (T2DM) patients with apical periodontitis (AP). Thirty individuals were divided into four groups: Healthy (H); with AP (AP); with T2DM (T2DM); and with T2DM and AP (T2DM-AP). Demographic and pharmacological data were registered. The body mass index (BMI) and the levels of glycated haemoglobin (HbA1c) and IL-1b, IL-6, IL-10, CCL3 and CCL4 were evaluated. AP areas were determined radiographically. Mean age was 64 AE 12 years, with 63% females. Most T2DM patients were under treatment with metformin and antihypertensives. BMI and H1bAc were significantly higher in T2DM patients in relation to H and AP groups. The AP areas were larger in the T2DM-AP group, compared with the AP group. These preliminary findings suggest no influence of AP on glycaemic control or inflammatory levels amongst T2DM patients, although T2DM increased the AP severity.

Is there any association between the presence of biomarkers and apical periodontitis? A systematic review

“…Later, 14 articles were removed because of non-compliance with PECO. For instance, tissue analysis (15)(16)(17)(18), absence of a control group (19)(20)(21)(22), and non-observational studies (23, 24), treatment analyses (25,26), microorganism analyses (27) and lack of information (28). Therefore, 17 articles remained in the systematic review (6,(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44) distributed across cross-sectional, cohort, and case-control studies, as shown in Figure 1.…”

Interaction between apical periodontitis and systemic disease (Review)

“…By contrast, a prospective clinical study with a 1-year follow-up period by Arya et al ( 67 ) suggested that endodontic treatment does not improve the levels of HbA1c in patients with DM. Furthermore, a pilot investigation indicated that AP does not affect levels of inflammatory markers or glycemic control in patients with T2DM ( 83 ). The limited sample size and uncontrolled confounding variables may partly explain the findings of the pilot study.…”